Halotestin
Halotestin Dragon Pharma 10 mg — Overview
Halotestin Dragon Pharma delivers fluoxymesterone — one of the most androgenic oral compounds ever synthesized — in a 10 mg tablet. Unlike the mass-building orals in the Dragon Pharma lineup, Halotestin is not used to add bodyweight. Its role is precise: a short, controlled burst of strength, aggression, and CNS drive for athletes who need peak force output on a specific date. Powerlifters use it in the final weeks before a meet, combat athletes use it pre-fight, and competitive bodybuilders add it to the last few weeks of pre-contest prep for hardness and aggression that no other oral can replicate. Available at Steroid Warehouse, Dragon Pharma Halotestin comes in a 10 mg tablet that allows flexible dosing within the 10–20 mg/day performance window.
One defining characteristic sets Halotestin apart from every other oral AAS: it does not aromatize. There is no estrogen conversion, no water retention, and no need for an aromatase inhibitor on a solo run. The compound's effect is purely androgenic — dry, hard, and intense, with zero estrogenic contribution.
About the Compound: Halotestin (Fluoxymesterone)
Fluoxymesterone is structurally modified testosterone with three key changes: a 9α-fluoro group, an 11β-hydroxyl group, and the 17α-methyl group for oral bioavailability. The fluorine atom at C-9 dramatically increases androgen receptor binding affinity while simultaneously blocking conversion by aromatase — explaining both the extreme androgenicity and the complete absence of estrogenic activity. The 11β-hydroxyl group prevents 5α-reductase from reducing the compound to a more active metabolite, but this does not protect against androgenic hair loss: fluoxymesterone activates androgen receptors in the scalp directly at very high potency, independent of DHT conversion. Finasteride has no effect on Halotestin-induced hair loss. The 17α-methyl group confers oral bioavailability at the cost of significant hepatic strain.
What It Does
Halotestin's effects are narrow and targeted. It does not produce the mass and estrogenic environment of Dianabol, and it does not produce the slow dry lean gains of Primobolan or Anavar. What it does is activate androgen receptors with extreme potency and stimulate the central nervous system in ways that translate directly to force output and competitive aggression.
- Maximal strength increase — androgen receptor activation in muscle and CNS enhances neuromuscular drive, inter-muscular coordination, and maximum force production, with noticeable effect within 1–2 weeks of starting
- CNS aggression and drive — the hallmark effect; users consistently report increased competitiveness, willingness to push past pain thresholds, and pre-training intensity that is distinct from any other oral steroid
- No water retention — fluoxymesterone does not aromatize; all strength gains are dry; bodyweight changes minimally relative to force output increase
- Hardness and vascularity — at low body fat, the absence of estrogenic activity and the androgenic effect on subcutaneous tissue produces enhanced muscle density and visible vascularity
- Moderate erythropoietic effect — androgen receptor activation in erythroid progenitor cells stimulates red blood cell production; the resulting increase in oxygen-carrying capacity contributes to work capacity under high-intensity output
- SHBG reduction — fluoxymesterone displaces testosterone from SHBG, briefly increasing free testosterone and amplifying the androgenic environment when a testosterone base is co-administered
- Rapid HPG suppression — endogenous testosterone production is suppressed within days of starting; natural testosterone is effectively at zero by the end of week one
Who It's For
Halotestin occupies a very specific position in performance pharmacology. It is not a general-purpose bulking or cutting agent. Its value comes entirely from the combination of extreme androgenicity and the complete absence of estrogenic activity — a profile suited to a narrow but well-defined set of use cases.
What sets it apart: Halotestin has an androgenic rating of approximately 1,900 — roughly 19 times the androgenicity of testosterone. No other commercially available oral AAS comes close. At the same time, the anabolic-to-androgenic ratio in practice strongly favors the androgenic axis. The result is a compound that dramatically increases strength and aggression while adding minimal scale weight — a combination no other oral can provide.
Ideal use cases:
- Powerlifters running a 3–4 week peak block before a competition, added onto a testosterone base that has been running for 10–16 weeks. No other oral provides the same immediate CNS force-output effect in this window.
- Combat sports athletes needing 3–4 weeks of aggression, explosiveness, and drive before a scheduled fight, where bodyweight impact must remain minimal.
- Advanced competitive bodybuilders in the final 3–4 weeks of pre-contest prep, when body fat is already very low and the goal is hardness, training intensity, and visual muscle density — stacked on a dry injectable base such as Masteron or Primobolan.
Who should choose something else: Anyone whose primary goal is muscle mass gain — Dianabol Dragon Pharma or injectable Anadrol are far more effective for that. Anyone with existing liver concerns or elevated baseline liver enzymes — Anavar 10 Dragon Pharma carries a fraction of the hepatotoxicity. Anyone who has not previously run at least one complete AAS cycle with bloodwork — Halotestin's aggressive liver strain and complete HPG suppression require baseline experience with cycle management. First-time oral users should start with Anavar 10 Dragon Pharma.
Halotestin vs Alternatives
| Compound | Key Differences | Choose Halotestin When | Choose Alternative When |
|---|---|---|---|
| Winstrol 10 Dragon Pharma Stanozolol 10 mg |
DHT-derived oral; strength + hardness with significantly less androgenic aggression; viable for 6–8 weeks; notably lower hepatotoxicity than Halotestin; mild effect on HDL; no CNS stimulation component | CNS aggression and maximal force output are the primary goals; very short window (3–4 wk); powerlifting or combat sports context requiring the extreme androgenic drive | Longer oral cycle needed (6–8 wk); user cannot tolerate extreme androgenic sides; dry hardness goal without the CNS activation; pre-contest stack where cycle duration matters |
| Anavar 10 Dragon Pharma Oxandrolone 10 mg |
Mildest oral AAS available; 6–10 week cycles viable; very low hepatotoxicity; appropriate for beginners and intermediate users; strength gain without aggression; no CNS stimulation; can be used by women at low doses | Extreme strength and aggression effect is specifically needed; short peak block (3–4 wk); experienced user with established bloodwork history and prior cycle management | First or second oral cycle; longer cycle desired; any hepatotoxicity concern; mass preservation during a cut is the primary goal; female use |
| Superdrol Dragon Pharma Methasterone 10 mg |
17-aa oral with comparable hepatotoxicity ceiling; primarily a mass + strength compound; produces meaningful lean mass gain; similar 4–6 week maximum; does not aromatize; different psychological profile — power increase without Halotestin's characteristic aggression signature | CNS aggression drive is specifically the goal; dry hard look without bodyweight increase; no mass gain desired | Lean mass gain alongside strength is the goal; similar hepatotoxicity is acceptable; a less extreme androgenic side effect profile is preferred |
Combinations
| Goal | Stack | Protocol / Timing | Notes |
|---|---|---|---|
| Powerlifting peak | Halotestin + Enantat 250 Dragon Pharma | Enantat 250 mg twice weekly throughout a 12–16 week base; add Halotestin 10–20 mg/day in the final 3–4 weeks before competition; stop Halotestin 24–48 hours after the meet | Enantat provides the anabolic base; Halotestin delivers the CNS peak exactly when needed. Math: 3 wk at 10 mg/day = 21 days × 10 mg = 210 mg → 21 tabs; 4 wk at 20 mg/day = 28 days × 20 mg = 560 mg → 56 tabs. Check AST/ALT before adding Halotestin to an already-running cycle. |
| Pre-contest hardening | Halotestin + Masteron 100 Dragon Pharma + Winstrol Inject Dragon Pharma | Masteron 100 mg EOD + Winstrol 50 mg EOD throughout the final 6–8 weeks of prep; add Halotestin 10–20 mg/day in the last 3–4 weeks; take the morning dose 1–2 hours before training sessions for peak CNS effect | Triple dry stack: Masteron adds density and anti-estrogenic hardness; Winstrol inject adds SHBG displacement and vascularity; Halotestin adds aggression and peak training intensity. Both Winstrol inject and Halotestin carry hepatic stress — check AST/ALT before combining and do not stack two 17-aa compounds simultaneously. |
| Combat sports burst | Halotestin solo or + low-dose testosterone base | Halotestin 10 mg/day × 3–4 weeks before a scheduled fight; if running alongside testosterone, limit to 100–150 mg/week as TRT-equivalent only; stop Halotestin 48–72 hours before weigh-in if water manipulation matters | Solo or minimal testosterone base keeps weight impact minimal — important for weight-class athletes. Even at 10 mg/day for 4 weeks (28 tabs), the psychological aggression effect is pronounced. Users new to Halotestin should assess their individual aggression response in training before using it in a competitive context. |
Side Effects & Management
| Side Effect | Severity | How to Handle It |
|---|---|---|
| Hepatotoxicity (liver enzyme elevation) | High — among the most hepatotoxic orals in common use | Start Liv.52 and Mucinac (NAC 600 mg/day) from day 1; add Ursocol (UDCA 300 mg twice daily) for cholestatic protection. Check AST/ALT every 2 weeks — stop the cycle immediately if either value exceeds 3× upper limit of normal (~120 U/L). Do not co-administer alcohol, acetaminophen, or other 17-aa orals. |
| Extreme aggression / mood disturbance | High — a performance feature at controlled doses; a liability at higher doses or outside the training context | Split the daily dose (morning + late afternoon); do not take the full dose at once. If irritability becomes unmanageable outside training, reduce dose by 5–10 mg/day or discontinue. This side effect is underestimated by first-time users — it is not simply "motivation," it is genuine behavioral agitation in a significant proportion of users. |
| Androgenic acne | High | Doxycycline for moderate persistent back and chest acne; Isotroin (Isotretinoin) for severe cystic cases — confirm clean liver function (AST/ALT within range) before adding isotretinoin alongside Halotestin. Daily cleansing routine reduces but does not eliminate androgenic acne. |
| Hair loss (androgenic alopecia) | High in genetically predisposed users | Finasteride is not effective for Halotestin-induced hair loss. The 9α-fluoro modification means fluoxymesterone's androgenicity at the hair follicle is direct and independent of the 5α-reductase pathway — blocking 5α-reductase has no impact. Minoxidil Dragon Pharma (topical or oral) is the practical pharmacological option for slowing androgenic hair loss during and after the cycle. |
| Lipid suppression (HDL reduction, LDL elevation) | High | Lipid panel at baseline and end of cycle. Post-cycle: Rosulip (Rosuvastatin) or Atorlip (Atorvastatin), or Atorvastatin 40 mg Dragon Pharma if HDL is markedly suppressed. Omega-3 fatty acids and regular cardiovascular work during cycle help manage HDL suppression actively. |
| Blood pressure elevation | Moderate | Monitor BP regularly during cycle. If sustained >140/90 mmHg: Amlip (Amlodipine) or Sartel (Telmisartan) as first-line. Add Ecosprin (Aspirin) 75 mg/day for cardiovascular protection throughout the cycle. |
| HPG axis suppression | Complete — testosterone production ceases within days | Full PCT is mandatory after every cycle, regardless of length. Do not skip PCT on the assumption that "it was only 4 weeks" — Halotestin suppresses HPG faster than most injectables, and recovery without SERM support is significantly slower. See PCT section. |
| Estrogenic sides (gynecomastia, water retention) | None | Halotestin does not aromatize. No estrogen-related sides occur on a solo cycle. No aromatase inhibitor is required. If testosterone is co-administered, manage estrogen per the testosterone dose as standard. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| AST / ALT (liver enzymes) | Baseline → every 2 weeks during cycle → end of cycle | AST and ALT within normal range (<40 U/L typical). Action threshold: stop Halotestin immediately if either value exceeds 3× upper limit of normal (~120 U/L). Biweekly testing is mandatory — not just baseline and end-of-cycle. |
| Hematocrit / CBC | Baseline → mid-cycle (week 3) → end of cycle | Hematocrit <52%; hemoglobin within normal range. Moderate erythropoietic effect expected. Values above 54% warrant dose reduction or temporary discontinuation. |
| Lipid panel (HDL, LDL, TG) | Baseline → end of cycle → 4 weeks post-PCT | HDL target >40 mg/dL on cycle; LDL <130 mg/dL. Significant HDL suppression is expected. Post-cycle statin (Rosulip or Atorlip) if HDL <35 mg/dL or LDL markedly elevated. Confirm lipid normalization at 4 weeks post-PCT. |
| E2 (Estradiol) | Baseline only (solo cycle); standard monitoring schedule if testosterone is co-administered | On a solo Halotestin cycle, E2 will not rise — no AI action required. If testosterone base is included, monitor E2 per that compound's dose (target: 20–40 pg/mL on cycle). |
| Blood pressure | Self-monitor every 2–3 days throughout cycle | Target <130/85 mmHg. Investigate and treat if sustained >140/90 mmHg: Amlip or Sartel first-line; reduce dose if BP does not respond to pharmacological management within 1 week. |
| LH + FSH | Baseline (pre-cycle) → 4–6 weeks post-PCT | Baseline confirms normal pre-cycle HPG function. Post-PCT recovery check: LH and FSH should return to lower-normal range within 4–6 weeks of completing PCT. Persistent suppression (<1 IU/L at 6 weeks post-PCT) warrants extended monitoring. |
| Total testosterone | Baseline (pre-cycle) → 4–6 weeks post-PCT | Baseline confirms pre-cycle normal range (300–1,000 ng/dL). Post-PCT target: return to ≥70% of baseline or lower-normal range. Values still below 250 ng/dL at 6 weeks post-PCT indicate slow recovery — extend PCT monitoring before any further cycle. |
PCT
Halotestin produces complete HPG axis suppression within days of the first dose. Testosterone recovery without SERM support after a Halotestin cycle is significantly slower than after most injectable testosterone cycles of comparable length. Full PCT is required after every Halotestin run, regardless of cycle duration.
PCT start timing: for a solo Halotestin cycle (no injectable base), start PCT 24–48 hours after the last tablet — the ~9-hour half-life means the compound clears rapidly. If Halotestin was run as an add-on to an injectable testosterone base, PCT start is determined by the injectable ester's clearance time, not by Halotestin's.
| Protocol Stage | Product | Dose | Duration |
|---|---|---|---|
| Pre-PCT (if total injectable cycle ≥12 weeks) | HCG 5000IU Dragon Pharma | 2,500 IU every 3 days (2–3 injections total) | 1 week before PCT start; stop HCG 3 days before beginning SERMs |
| PCT Weeks 1–2 | Clomid Dragon Pharma | 50 mg/day | 2 weeks |
| PCT Weeks 1–2 | Nolvadex Dragon Pharma | 20 mg/day | 2 weeks |
| PCT Weeks 3–4 | Clomid Dragon Pharma | 25 mg/day | 2 weeks |
| PCT Weeks 3–4 | Nolvadex Dragon Pharma | 10 mg/day | 2 weeks |
| Alternative if Clomid visual side effects occur | Enclomiphene Dragon Pharma | 25 mg/day | 4 weeks (replaces Clomid; keep Nolvadex alongside) |
Practical Summary
- 4–6 week hard limit — no exceptions: Halotestin's hepatotoxicity is cumulative; AST/ALT must be checked every 2 weeks; stop immediately if either value exceeds 3× upper normal limit
- Split the daily dose: ~9-hour half-life requires two administrations; take the larger portion 1–2 hours pre-training for peak CNS effect; taking the full day's dose at once wastes the second half-life window and concentrates the hepatic load
- No AI needed on solo cycles: fluoxymesterone does not aromatize; skip anastrozole entirely; only manage estrogen if a testosterone base is co-administered, and dose the AI per the testosterone component only
- Liver support from day 1, not from the first symptoms: Liv.52 + NAC (Mucinac) + UDCA (Ursocol) start with the first tablet; waiting until enzymes rise defeats the purpose of hepatoprotection
- Finasteride does not protect the scalp on Halotestin: the 9α-fluoro modification makes fluoxymesterone's androgenicity at hair follicles direct and 5α-reductase-independent; Minoxidil Dragon Pharma is the practical countermeasure
- PCT is mandatory even for short cycles: HPG suppression is complete within days; start Clomid Dragon Pharma + Nolvadex Dragon Pharma 24–48 hours after the last tablet; confirm testosterone recovery with bloodwork 4–6 weeks post-PCT before planning any further cycle
Halotestin remains one of the most powerful androgenic tools available, used by powerlifters, combat athletes, and competitive bodybuilders who need a short, targeted boost in strength and aggression. Its effect on CNS drive and force output is unmatched among oral compounds — but those gains come with some of the strictest usage rules in performance pharmacology. Cycle ceilings are not recommendations; they are dictated by hepatotoxicity and liver enzyme response. For athletes who respect those boundaries, follow bloodwork protocols, and complete a full PCT, Dragon Pharma Halotestin at Steroid Warehouse delivers exactly what it promises: a focused, time-limited strength advantage.
References
| Source | Topic | Link |
|---|---|---|
| British Journal of Pharmacology / PubMed | Kicman 2008 — comprehensive review of anabolic steroid pharmacology, covering androgen receptor activity, structure-activity relationships, anabolic-androgenic effects, clinical applications, misuse patterns, and adverse effect profiles across AAS compound classes | Kicman AT (2008) ↗ |
| Seminars in Liver Disease / PubMed | Ishak & Zimmerman 1987 — classic review of hepatotoxic effects caused by anabolic-androgenic steroids, including cholestasis, peliosis hepatis, nodular regenerative changes, hepatic adenomas, hepatocellular carcinoma, and other liver complications linked to androgenic steroid exposure | Ishak KG & Zimmerman HJ (1987) ↗ |
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks, showing increased fat-free mass, muscle size, and strength, especially when combined with resistance training; foundational evidence for supraphysiologic androgen anabolic effects | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — synthetic testosterone-derived AAS pharmacology, androgen receptor mechanism, anabolic-androgenic effects, 17α-alkylated oral steroid context including fluoxymesterone, misuse patterns, monitoring, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — testosterone and androgen derivative mechanisms of action, androgen receptor activity, HPG axis suppression, estradiol aromatization, androgen pharmacology, and hepatotoxic 17α-alkylated oral androgen context including fluoxymesterone | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
What is Halotestin?
Halotestin (Fluoxymesterone) is an oral steroid for strength and aggression; see What is Fluoxymesterone. It enhances performance—consult professionals for safe use.
How to use Halotestin?
Take 10-40 mg daily, split doses; see How to Use. Use with liver support—consult for tailored plans.
What does Halotestin do?
It boosts strength and aggression without mass gain; see Mechanism of Action. It delivers power—monitor with labs.
What are the side effects of Halotestin?
Side effects include liver strain and aggression; see Side Effects. Manage with monitoring—consult professionals for safety.
How long does Halotestin stay in your system?
With a 9-10 hour half-life, it's detectable for 2-3 months; see Mechanism of Action. Plan PCT—consult professionals.
How does Halotestin work?
Halotestin works through strong androgen receptor activity that may support:
- Strength output
- Nervous system stimulation
- Training intensity and aggression-related effects
- Muscle hardness and conditioning support
It is often discussed more for strength and performance than for large muscle mass gains.
How quickly does Halotestin take effect?
Halotestin is fast-acting due to its oral form. Users often report noticeable increases in strength and aggression within a short period after starting use.
Is Halotestin used for bulking or cutting?
Halotestin is not typically used for mass-building or traditional bulking. It is more often associated with short-term strength or performance-focused phases.
Related Products
